Ion; 2011.doi:ten.11861475-2875-12-450 Cite this short article as: Quashie et
Ion; 2011.doi:ten.11861475-2875-12-450 Cite this short article as: Quashie et al.: A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum FGFR4 list Clinical isolates to a panel of anti-malarial drugs. Malaria Journal 2013 12:450.Submit your next manuscript to BioMed Central and take full advantage of:Easy on the web submission Thorough peer overview No space constraints or color figure charges Instant publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Analysis which can be freely available for redistributionSubmit your manuscript at biomedcentralsubmit
HIPPOKRATIA 2013, 17, two:187-CASE REPORTBleomycin cardiotoxicity for the duration of chemotherapy for an ovarian germ cell tumorDidagelos M, Boutis A, Diamantopoulos N, Sotiriadou M, Fotiou C1st Division of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, Thessaloniki, GreeceAbstract Introduction: Platinum-based chemotherapeutic regimens, such as BEP (bleomycin, etoposide, cisplatin) represent the typical of care, initial line therapy in non-epithelial ovarian tumours. Cardiovascular toxicity is really a uncommon 5-HT1 Receptor Compound adverse effect of bleomycin. Case Report: A 41-year-old lady with ovarian granulosa tumor, treated with very first line BEP chemotherapy knowledgeable chest discomfort rapidly progressing to serious precordial discomfort for the duration of bleomycin infusion. The infusion was stopped and electrocardiographic alterations indicative of myocardial ischemia have been revealed. Anti-anginal and anti-thrombotic therapy was introduced. Cardiac enzymes weren’t elevated and echocardiographic findings showed no wall motion abnormalities. Twenty four hours after the episode the elctrocardiographic changes insisted and chemotherapy was decided to be continued, excluding bleomycin, with no symptom recurrence. Discussion: Cardiovascular complications pose a uncommon but prospective fatal adverse effect of BEP chemotherapy and should be carefully addressed, specially in individuals with additional cardiovascular risk components. Physicians dealing with bleomycin-based therapies might locate this understanding valuable for a more comprehensive evaluation of chest pain syndromes in these sufferers. Hippokratia 2013, 17, two: 1787-188 Keywords and phrases: BEP chemotherapy, ovarian cancer, cardiotoxicity, myocardial ischemia, chest painCorresponding Author: Anastasios Boutis, 1st Division of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, 54007, Thessaloniki, Greece, tel.: 302310898711, 306937040299, fax:302310845514, e-mail: alboutisotenet.grIntroduction BEP (bleomycin, etoposide, cisplatin) chemotherapeutic regimen represents the common of care initially line therapy in non-epithelial ovarian tumours1. Cardiovascular toxicity is a rare adverse impact of bleomycin and could be expressed clinically as hypotension, pericarditis, acute substernal chest discomfort, coronary artery illness, myocardial ischemia, myocardial infarction, cerebral vascular accident and Raynaud’s phenomenon2. Case report A 41-year-old woman with sophisticated recurrent ovarian cancer (adult granulosa cell tumor, initial stage pT2b pN1 M0, FIGO IIIC, 4 years prior to) was treated with initially line platinum-based chemotherapy. Pre-treatment cardiovascular threat elements included arterial hypertension (properly controlled with angiotensin II receptor blockers) and obesity (BMI: 40.3 Kgm2). Baseline cardiologic evaluation with ECG and echocardiogram just just before initiation of chemotherapy was unremarkable. For the duration of the first cycle of therapy and throughout the bleomycin infusion, ch.